Navigation Links
New Study Published in the Journal of Drugs in Dermatology Finds DOT Microablative CO2 Laser Optimum for Skin Rejuvenation
Date:3/5/2009

DALLAS, March 5 /PRNewswire/ -- A study published by Deborah S. Sarnoff, M.D. et al in the February issue of the Journal of Drugs in Dermatology explores the new generation of carbon dioxide (CO2) laser skin resurfacing technologies, specifically, the SmartXide DOT(TM) laser. DOT utilizes a fractional or microablative approach to treating the skin allowing for rapid healing, less downtime and profound results. Dr. Sarnoff is a board certified dermatologist and clinical professor of Dermatology at NYU Medical Center.

As consumers have become savvier to skin care and laser options, the pendulum is swinging back to more result-oriented treatments. With the saturation of non-ablative lasers, skin tightening devices and chemical peels, patients are looking for an alternative treatment that offers exceptional results with fewer treatments and less time in the doctor's office. What these procedures can do in 4-5 treatments, the DOT technology can do in a single treatment and results have been far superior to anything on the market today.

By combining the CO2 laser with a fractionated technique, the latest innovation in skin rejuvenation, DOT (Dermal Optical Thermolysis), has become the optimal choice for active patients desiring significant effects from a single treatment with minimal downtime. Additionally, DOT Therapy is ideal in causing immediate contraction of wrinkles and loose skin, results that non-ablative lasers produce in a time span of about six months.

Dr. Sarnoff's study examined 32 patients ages 33-76 over a six-month period who underwent a single laser resurfacing procedure with the DOT technology. Areas treated included the face, neck, trunk and hands. Results demonstrated over 50% improvement in almost all of the patients. Those treated for wrinkles, hyperpigmentation and sun damage showed over 75% improvement.

Why It Works

The D
'/>"/>

SOURCE Eclipsemed
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
2. Harvard Study Shows Folic Acid, B Vitamins in Animi-3(R) May Prevent Vision Loss
3. Pioneering Diamyd(R) Study to Prevent Childhood Diabetes Approved
4. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
5. TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee
6. Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study
7. Laser Burn Injuries in One Eye Can Disrupt Protective Immune Privilege in Both Eyes, Study Finds
8. Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmers Trabecular Metal(TM) Technology
9. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
10. Childrens Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia
11. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "US Self-monitoring Blood Glucose Market" report to their ... This market insight focuses on the developments in ... United States . Reimbursement analysis and the effects ... for more than 73 SMBG meters have been performed, ...
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
(Date:12/22/2014)... 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... the following open letter to shareholders from President ... Sc. Dear RXi Shareholders, ... inaccurate statements posted on certain social media sites ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Switzerland, June 20, Actelion Ltd (SWX: ATLN) announced ... in mildly symptomatic pulmonary,arterial hypertension (PAH) patients (WHO ... prevented clinical deterioration by significantly,delaying time to clinical ... WHO FC III/IV. A significant reduction in pulmonary ...
... Inc.,(Nasdaq: TRBN ) today announced that Wyeth ... has exercised its option under the terms of ... period for an,additional one-year period through Dec. 22, ... Wyeth,s obligations to Trubion include,collaboration research funding commitments ...
Cached Medicine Technology:Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 2Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 3Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 4Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 5Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 6Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 3
(Date:12/22/2014)... Only weeks following the announcement that Henderson, Nevada ... a battery manufacturer create 29 well-paying jobs in Mojave ... launching in Henderson to deliver yet another win ... sector is going to build a stronger middle class ... works with small businesses that rely on middle class ...
(Date:12/22/2014)... December 22, 2014 In recognition of ... sales to Hero Reward, a local organization that provides ... , Located on a couple hundred acres ... Program offers lodging, world class fishing, hunting, hiking, horseback ... was founded several years ago to support U.S. Service ...
(Date:12/22/2014)... Pasadena sleep apnea dentist, ... apnea. Drowsy drivers are 15 times more likely to ... and some experts believe that sleep-deprived drivers may be ... Unfortunately, millions of Americans may be sleep-deprived without even ... Medicine, about 18 million Americans have sleep apnea, but ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again ... provide logistics and support for one of Dallas’ largest holiday ... history of giving back to the community in which it ... Drive were Whataburger® and 99.5 The Wolf. , There is ... gifts to children who would otherwise not receive any is ...
Breaking Medicine News(10 mins):Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... discovered an accomplice in breast cancer a master control ... reactions orchestrated by a cancer-causing gene (or oncogene) named Wnt1. ... back-to-back papers featured on the cover of the August 15 ... about the regulation of a Wnt oncogene," explains lead author ...
... By Jenifer Goodwin HealthDay Reporter , ... mistakes, admitting the error, saying "I,m sorry" and offering ... lawsuits, new research shows. In 2001, University ... workers to report medical mistakes. The program included a ...
... Supports (CLASS) Act a largely overlooked component of the ... potential to transform long-term care financing in the United States ... latest issue of Public Policy & Aging Report ... The SCAN Foundation , this installment of PPAR ...
... This release is available in French . ... boys with low parental monitoring are more likely to befriend ... to a new study published in the journal Addictive ... de Montral and Sainte-Justine University Hospital Research Center found that ...
... fellow Amy Speed-Andrews has examined how a specialized Iyengar yoga ... who have completed treatment, makes a difference in their recovery. ... to fill out a questionnaire about their physical and mental ... yoga and again at the end. After analyzing the data ...
... are developing the first device able to transmit American ... just completing its initial field test by participants in ... "This is the first study of how deaf people ... project leader Eve Riskin, a UW professor of electrical ...
Cached Medicine News:Health News:Researchers identify breast cancer culprits 2Health News:When Doctors Admit Mistakes, Fewer Malpractice Suits Result, Study Says 2Health News:When Doctors Admit Mistakes, Fewer Malpractice Suits Result, Study Says 3Health News:CLASS Act analysis reveals America's long-term care future 2Health News:Heavy drug-use among bad boys curbed by parental monitoring and peers 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 3
... Delivery System (CDS) facilitates the ... the Aescula LV Left-Heart Lead. ... patented coronary sinus curve that ... access to the coronary sinus ...
... PCS2 system is Haemonetics ... collection of plasma and ... the collection of "jumbo" ... platelet-poor plasma with optional ...
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
... provides quick, convenient, repetitive dispensing for ... have a polyethylene plunger and a ... use with most reagents. Application: ... separate volumes can be selected for ...
Medicine Products: